Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2276 - 2300 of 2733 in total
The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases. SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La...
Investigational
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
Matched Description: … KB002 is an engineered human IgG1k antibody engineered human. …
A combination of docosahexaenoic Acid (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.
Investigational
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19
Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase. [MeSH]
Investigational
Matched Description: … Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the …
Experimental
Matched Iupac: … methyl-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8,18-pentaene-19
Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19). INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum.
Investigational
Matched Description: … Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19
Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
Investigational
Matched Categories: … Recombinant Proteins …
Investigational
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Investigational
Matched Description: … single chain variable fragment with affinity for human CD38 cell surface protein. ... 0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human
Component of human seminal plasma & spermatozoa.
Experimental
Matched Description: … Component of human seminal plasma & spermatozoa. …
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigational
Matched Description: … solid tumors and human leukemias, often leading to durable responses. ... Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human
Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells by protecting against destruction of host cells mediated by the toxin.
Investigational
Matched Description: … Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin ... or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells …
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program …
Zastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known as astuprotimut-R. It is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).
Investigational
Matched Description: … Zastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known …
VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). It is being investigated in Wilson Disease.
Investigational
Matched Description: … VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an …
10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).
Investigational
Matched Iupac: … (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa- …
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Investigational
UX053 is an mRNA encoding the human glycogen debranching enzyme.
Investigational
Matched Description: … UX053 is an mRNA encoding the human glycogen debranching enzyme. …
SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma).
Investigational
Matched Description: … SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. …
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant
CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS using the Abgenix XenoMouse technology.
Investigational
Matched Description: … CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor ... CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). …
INH-A21 is a human staphylococcal immunoglobulin
Investigational
Matched Description: … INH-A21 is a human staphylococcal immunoglobulin …
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. ... HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced …
Displaying drugs 2276 - 2300 of 2733 in total